Immutep Ltd (ASX: IMM) Share Price and News

Price

$0.235

Movement

0.01 (+4.44%)

as at 17 Apr - Closed (20 mins delayed)

52 Week Range

$0.2225 - $0.4805

 
1 Year Return

-32.23%

Immutep Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $343.19 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 1.46 billion
Earnings per share -0.033
Dividend per share N/A
Year To Date Return -38.36%
Earnings Yield N/A
Franking -
Share Price

$0.235

Day Change

0.01 (+4.44%)

52 Week Range

$0.2225 - $0.4805

Yesterday's Close

$0.225

Today's Open

$0.235

Days Range

$0.23 - $0.245

Volume

1,242,353

Avg. Volume (1 month)

5,009,798

Turnover

$294,048

as at 17 Apr - Closed

  • Immutep Ltd (ASX: IMM)
    Latest News

    four excited doctors with their hands in the air
    Share Gainers

    The Immutep (ASX:IMM) share price is up 25% in a month and could go higher

    This biotech company's shares have been on fire...

    Read more »

    stock market gaining
    Share Gainers

    Why BlueBet, Dicker Data, Immutep, & Sandfire are charging higher

    These ASX shares are starting the month strongly...

    Read more »

    smiling health care workers in a medical setting
    Healthcare Shares

    Why the Immutep (ASX:IMM) share price is leaping 5% today

    Immutep is one step closer to finishing its TACTI-002 trial.

    Read more »

    man jumping along increasing bar graph signifying jump in alumina share price
    Share Gainers

    Immutep (ASX:IMM) share price jumps 5% on Chinese patent grant

    Immutep shares make their walk northwards after a patent was granted on Friday.

    Read more »

    Rising healthcare ASX share price represented by doctor giving thumbs up
    Healthcare Shares

    Why the Immutep (ASX:IMM) share price is charging higher today

    Researchers are pursuing the silver bullet to defeat cancer.

    Read more »

    woman in lab coat conducting testing representing biotech
    Share Market News

    Capital keeps flowing into ASX Biotech shares in 2021

    What is driving capital inflow into ASX biotech shares?

    Read more »

    three excited doctors with hands in the air
    Healthcare Shares

    The 5 best performing ASX healthcare shares of FY21, did yours make the cut?

    These ASX shares had the healthiest gains in the last financial year...

    Read more »

    woman in lab coat conducting testing representing biotech
    Healthcare Shares

    The Immutep (ASX:IMM) share price is up 6% today

    Immutep has received all the approvals it needs to begin its latest trial in the United States.

    Read more »

    An ASX investor looks devastated as he watches his computer screen, indicating bad news
    Share Fallers

    Why the Immutep (ASX:IMM) share price is sinking 16% today

    This biotech has started the week deep in the red...

    Read more »

    a doctor looking up at question marks
    Healthcare Shares

    Here's why the Immutep (ASX:IMM) share price is frozen

    The company's shares will remain in a trading halt until Monday or pending a further update.

    Read more »

    Young doctor raising arms in air with hands in fists celebrating a new development
    Healthcare Shares

    Why the Immutep (ASX:IMM) share price is marching higher today

    While the world is focused on COVID, the search for better cancer treatments continues apace.

    Read more »

    woman carrying out an experiment with a pipette and petri dish
    Healthcare Shares

    Immutep (ASX:IMM) share price backtracks despite patent approval

    The announcement of a new European patent was not sufficient to keep the biotech in the green today.

    Read more »

    Frequently Asked Questions

    IMM ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Immutep Ltd

    Immutep Ltd (ASX: IMM) is a biotechnology company developing immunotherapy products for cancer and autoimmune diseases. The company describes itself as a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Immutep's LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune diseases. Immutep currently has three clinical-stage candidates and two earlier-stage candidates.

    IMM Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    16 Apr 2025 $0.23 $-0.01 -4.35% 2,493,294 $0.23 $0.23 $0.22
    15 Apr 2025 $0.23 $-0.02 -8.16% 1,795,873 $0.24 $0.24 $0.23
    14 Apr 2025 $0.25 $0.01 4.17% 2,448,967 $0.24 $0.25 $0.24
    11 Apr 2025 $0.24 $0.00 0.00% 1,470,584 $0.24 $0.24 $0.24
    10 Apr 2025 $0.24 $0.01 4.26% 1,746,118 $0.26 $0.26 $0.24
    09 Apr 2025 $0.24 $-0.02 -8.00% 1,709,481 $0.25 $0.25 $0.23
    08 Apr 2025 $0.25 $0.02 8.51% 1,754,010 $0.24 $0.25 $0.24
    07 Apr 2025 $0.24 $-0.02 -7.84% 46,075,259 $0.24 $0.24 $0.23
    04 Apr 2025 $0.26 $-0.01 -3.85% 987,956 $0.26 $0.26 $0.25
    03 Apr 2025 $0.26 $-0.01 -3.77% 14,133,354 $0.26 $0.27 $0.25
    02 Apr 2025 $0.27 $-0.02 -7.14% 21,057,180 $0.28 $0.28 $0.26
    01 Apr 2025 $0.28 $0.00 0.00% 956,683 $0.28 $0.29 $0.28
    31 Mar 2025 $0.28 $-0.01 -3.45% 1,194,931 $0.29 $0.29 $0.28
    28 Mar 2025 $0.29 $0.01 3.51% 4,401,662 $0.29 $0.30 $0.29
    27 Mar 2025 $0.29 $-0.02 -6.67% 570,040 $0.30 $0.30 $0.29
    26 Mar 2025 $0.30 $0.01 3.45% 2,097,887 $0.29 $0.31 $0.28
    25 Mar 2025 $0.29 $0.01 3.51% 900,779 $0.29 $0.30 $0.28
    24 Mar 2025 $0.29 $-0.03 -9.68% 3,169,728 $0.31 $0.32 $0.28
    21 Mar 2025 $0.31 $0.01 3.28% 1,293,122 $0.30 $0.32 $0.30
    20 Mar 2025 $0.31 $0.00 0.00% 1,081,471 $0.30 $0.31 $0.30
    19 Mar 2025 $0.31 $0.01 3.39% 1,774,316 $0.30 $0.31 $0.29
    18 Mar 2025 $0.30 $0.01 3.51% 994,933 $0.29 $0.30 $0.29

    Profile

    since

    Note